Cliff Asness’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34M Buy
934,326
+218,080
+30% +$6.88M 0.01% 957
2026
Q1
$20.1M Sell
716,246
-97,643
-12% -$3.2M 0.01% 1031
2025
Q4
$30.5M Buy
813,889
+458,321
+129% +$15.1M 0.02% 813
2025
Q3
$9.8M Buy
355,568
+203,539
+134% +$7.01M 0.01% 1104
2025
Q2
$4.8M Sell
152,029
-14,311
-9% -$460K ﹤0.01% 1309
2025
Q1
$5.52M Buy
166,340
+7,484
+5% +$268K 0.01% 1087
2024
Q4
$5.47M Buy
158,856
+16,271
+11% +$559K 0.01% 1060
2024
Q3
$5.7M Sell
142,585
-11,760
-8% -$413K 0.01% 993
2024
Q2
$4.66M Buy
154,345
+1,116
+0.7% +$33.6K 0.01% 1054
2024
Q1
$5.15M Sell
153,229
-26,526
-15% -$851K 0.01% 974
2023
Q4
$5.81M Buy
179,755
+11,236
+7% +$314K 0.01% 886
2023
Q3
$5.52M Buy
168,519
+22,126
+15% +$768K 0.01% 876
2023
Q2
$5.15M Buy
146,393
+92,843
+173% +$3.21M 0.01% 889
2023
Q1
$1.75M Buy
53,550
+21,627
+68% +$985K ﹤0.01% 1311
2022
Q4
$1.76M Sell
31,923
-1,453
-4% -$79.9K ﹤0.01% 1311
2022
Q3
$1.48M Buy
33,376
+22,653
+211% +$1.1M ﹤0.01% 1337
2022
Q2
$523K Buy
+10,723
New +$483K ﹤0.01% 1669

Other funds holding HRMY

Cliff Asness's HRMY Position: Q2 2026 in Review

Cliff Asness increased its Harmony Biosciences (HRMY) stake by 30% in Q2 2026, buying an estimated $6.88M and bringing the position to 934,326 shares worth $34M. The position accounts for 0.01% of the portfolio, ranked #957.

Cliff Asness first reported a position in HRMY in Q2 2022 and has held it in 17 quarters since. 325 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Cliff Asness held 934,326 shares of Harmony Biosciences worth $34M as of Q2 2026.
  • Cliff Asness bought 218,080 Harmony Biosciences shares in Q2 2026, an estimated $6.88M.
  • Harmony Biosciences made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #957 holding.
  • Cliff Asness first reported a position in Harmony Biosciences in Q2 2022 and has held it in 17 quarters since.
  • 325 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.